Cencora Analyst Ratings
Leerink Partners Maintains Outperform on Cencora, Maintains $275 Price Target
Cencora Inc: Baird raises price target from $277 to $280
Analysts Are Bullish on Top Healthcare Stocks: Teva Pharmaceutical (TEVA), Cencora (COR)
Analysts' Top Healthcare Picks: Inspire Medical Systems (INSP), Cencora (COR)
JPMorgan Adjusts Price Target on Cencora to $280 From $270
Jefferies Adjusts Price Target on Cencora to $230 From $235
Wells Fargo Adjusts Cencora Price Target to $236 From $235
Evercore ISI Adjusts Cencora Price Target to $260 From $270
Baird: Maintaining the Cencora (COR.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $275.00 to $277.00.
Cencora Analyst Ratings
Baird Maintains Outperform on Cencora, Raises Price Target to $277
Cencora: A Balanced View Amidst Mixed Financial Indicators – Hold Rating Maintained
Cencora Analyst Ratings
Citigroup Adjusts Price Target on Cencora to $280 From $265
Cencora (COR) Receives a Buy From Barclays
Analysts Have Conflicting Sentiments on These Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Inspire Medical Systems (INSP) and Cencora (COR)
Analysts Offer Insights on Healthcare Companies: Cencora (COR), Cormedix (CRMD) and NeueHealth Inc (NEUE)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (COR) and Clearside Biomedical (CLSD)
Leerink Partners Initiates Coverage On Cencora With Outperform Rating, Announces Price Target of $261